Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-16-022173
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-08 19:09:27
Reporting Period:
2016-06-08
Filing Date:
2016-06-08
Accepted Time:
2016-06-08 19:09:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1369868 China Biologic Products Inc. CBPO () NY
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
929408 Warburg Pincus & Co.
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1162870 Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
No No Yes No
1414561 Warburg Pincus X, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1414564 L.p. Gp X Pincus Warburg C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1414565 Warburg Pincus Private Equity X, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1451560 Warburg Pincus X Partners, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1575882 Wp X Biologics Llc C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1621224 Warburg Pincus Partners Gp Llc C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1621242 Warburg Pincus Partners, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1621874 Wpp Gp Llc C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-06-08 2,775,000 $111.00 1,312,200 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain underwriting agreement dated June 2, 2016 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds"), WP X Biologics LLC, a Delaware limited liability company ("WP X B"), and Morgan Stanley & Co. International plc, as the underwriter named in the Underwriting Agreement (the "Underwriter"). At the closing of the transaction contemplated under the Underwriting Agreement, on June 8, 2016, WP X B and the Funds sold an aggregate of 2,775,000 shares of Common Stock to the Underwriter for a purchase price of $308,025,000.00, or $111.00 per share.
  2. As of June 8, 2016, WP X B is the holder of an aggregate of 1,312,200 shares of Common Stock of the Issuer. WP X B is owned 96.9% by WP X and 3.1% by WPP X, and therefore, WP X may be deemed to beneficially own 1,271,522 shares of Common Stock, and WPP X may be deemed to beneficially own 40,678 shares of Common Stock. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), and the general partner of WP X GP,
  3. (Continued from footnote 2) Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company ("WP"), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC"), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a "Warburg Pincus Reporting Person" and collectively, the "Warburg Pincus Reporting Persons") may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer held by the Funds and WP X B. Messrs. Kaye and Landy may be deemed to control WP X B, the Funds, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC.
  4. Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Person, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person.
  5. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than WP X B and the Funds, herein states that this Form 4 shall not be deemed an admission that it or he is the beneficial owner of any of the shares of Common Stock of the Issuer reported in this Form 4. Each of WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock of the Issuer, except to the extent of its or his pecuniary interest in such shares of Common Stock.